Upstream Bio to Present Phase 2 VIBRANT Verekitug Data on Nasal Polyps and Asthma
Upstream Bio will present Phase 2 VIBRANT trial data on verekitug, the only TSLP receptor antagonist, for chronic rhinosinusitis with nasal polyps and comorbid asthma at the ATS 2026 Conference in Orlando on May 18. Two posters (P1397, P1398) in session B32 will detail clinical outcomes and biomarker changes.
1. Upcoming ATS Presentations
Upstream Bio has scheduled two poster presentations on May 18, 2026, at the American Thoracic Society International Conference in Orlando. Both posters (P1397 and P1398) will be displayed during session B32 – Rise of the Biologics: A New Hope for Breathing Easier – from 11:30 AM to 1:15 PM ET.
2. VIBRANT Trial and Verekitug
The presentations will feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only antagonist targeting the thymic stromal lymphopoietin receptor in clinical development. This monoclonal antibody is being tested in separate Phase 2 studies for chronic rhinosinusitis with nasal polyps, severe asthma and COPD.
3. Focus on Clinical Effects and Biomarkers
Poster P1397 will report verekitug’s clinical effects in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma, while Poster P1398 will examine its impact on type 2 inflammatory biomarkers in nasal tissue and blood samples. These data aim to demonstrate both symptom improvement and underlying inflammatory modulation.
4. Implications for Upstream Bio
Positive findings could bolster verekitug’s positioning in a competitive biologics market by highlighting its unique mechanism upstream of multiple inflammatory cascades. Investors will be watching for efficacy signals that could accelerate partnerships, late-stage planning and regulatory discussions.